Prokarium - About the company
Prokarium is a series C company based in London (United Kingdom), founded in 2012. It operates as a Developer of bacterial immunotherapy treatments for various types of cancer. Prokarium has raised $70M in funding from Riyadh Valley Company and Korea Investment Holdings, with a current valuation of £*****. The company has 207 active competitors, including 48 funded and 50 that have exited. Its top competitors include companies like Vaxart, Insmed and Evofem.
Company Details
Developer of bacterial immunotherapy treatments for various types of cancer. The company leverages synthetic biology to reprogram bacteria specifically using its proprietary ZH9 strain to function as a therapeutic delivery platform for oncology and other medical applications.
- Website
- www.prokarium.com/
- Phone Number
- +55 **********
- Registered Address
- London Bioscience Innovation Centre, 2 Royal College Street, London, NW1 0NH
Key Metrics
Founded Year
2012
Location
London, United Kingdom
Stage
Series C
Total Funding
$70M in 6 rounds
Latest Funding Round
Post Money Valuation
£***** as on Jan 10, 2023
Investors
Ranked
16th among 207 active competitors
Employee Count
24 as on Dec 31, 2025
Legal entities associated with Prokarium
Prokarium is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
PROKARIUM HOLDINGS LTD CIN: 8933971 , United Kingdom, Active | - | 12 (As on Dec 31, 2025) | ||
Prokarium Limited CIN: 6300883 , Germany, Active | Jul 02, 2017 | - | 12 (As on Dec 31, 2025) |
Sign up to download Prokarium's company profile
Prokarium's funding and investors
Prokarium has raised a total funding of $70M over 6 rounds. Its first funding round was on Aug 03, 2015. Its latest funding round was a Series C round on Jan 10, 2023 for $*****. 1 investor participated in its latest round. Prokarium has 9 institutional investors and 2 angel investors.
Here is the list of recent funding rounds of Prokarium:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 10, 2023 | 1394359 | Series C | 4573669 | 6891208 | 2604951 | 2425478 |
Oct 26, 2020 | 3054190 | Series B | 1296479 | 8200928 | 8148705 | |
Oct 08, 2019 | 4978276 | Grant (prize money) | 1912479 | 4553136 | 2650290 |
Access funding benchmarks and valuations. Sign up today!View details of Prokarium's funding rounds and investors
Prokarium's founders and board of directors
Founder? Claim ProfileHere are the details of Prokarium's key team members:
- Ibraheem Mahmood: CEO of Prokarium. They serve on the board of 1 company.
Prokarium's Board of Directors
Prokarium's board has 3 active members. Ted Fjallman is part of team and Kristen Albright and Thomas Bengt Eldered are independent board members.Here is the list of Prokarium's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
oqnwzya | Team | - | Current | 5y 5m |
Independent board member | - | Current | 0y 10m | |
vk{soji | Independent board member | - | Current | 6y 2m |
View details of Prokarium's Founder profiles and Board Members
Prokarium's employee count trend
Prokarium has 24 employees as of Dec 25. The total employee count is 25.0% lower than what it was in Dec 24. Here is Prokarium's employee count trend over the years:
Uncover Prokarium's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Prokarium's Competitors and alternates
Top competitors of Prokarium include Vaxart, Insmed and Evofem. Here is the list of Top 10 competitors of Prokarium, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Vaxart 2004, San Francisco (United States), Public | Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 67/100 | |
2nd | Insmed 1999, Bridgewater (United States), Public | Developer of small molecule inhibitors for rare lung diseases | - | 66/100 | |
3rd | Evofem 2009, San Diego (United States), Public | Developer of sexual and reproductive health therapeutics | $100M | 65/100 | |
4th | UroGen Pharma 2004, Ra anana (Israel), Public | Developer of therapeutics to treat urothelial and specialty cancers | $7M | 63/100 | |
5th | Basilea 1999, Basel (Switzerland), Public | Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases | - | 59/100 | |
6th |  TuHURA Biosciences 1996, Tampa (United States), Public | Developer of immunotherapies for the treatment of cancer | $41.5M | 58/100 | |
7th | Centauri Therapeutics 2014, Kent (United Kingdom), Series A | Developer of immunotherapeutics to treat infectious diseases | $73M | 58/100 | |
8th | Lipella 2005, Pittsburgh (United States), Public | Developer of lipid-based therapies for common bladder syndromes | $3.37M | 57/100 | |
9th |  CanSino Biologics 2009, Tianjin (China), Public | Developer of vaccines for the treatment of infectious diseases | $105M | 56/100 | |
10th | Eubiologics 2012, Seoul (South Korea), Public | Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems. | $7.5M | 56/100 | |
16th |  Prokarium 2012, London (United Kingdom), Series C | Developer of bacterial immunotherapy treatments for various types of cancer | $70M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Prokarium's competitors? Click here to see the top ones
Prokarium's Investments and acquisitions
Prokarium has made no investments or acquisitions yet.
Reports related to Prokarium
Here is the latest report on Prokarium's sector:
News related to Prokarium
Filter this listMedia has covered Prokarium for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
•
•
Prokarium bolsters IP portfolio with two new US patentsPharmaceutical Technology•Nov 04, 2024•Prokarium
•
Prokarium Expands IP Portfolio With Two New U.S. Patents Strengthening Its Position in Bladder CancerBusiness Wire•Nov 01, 2024•Prokarium
•
Prokarium Reaches Milestone with First Patient Dose in PARADIGM-1 Clinical Trial for Non-Muscle Invasive Bladder CancerBusiness Wire•Feb 08, 2024•Prokarium
•
Prokarium reaches milestone with first patient dose in clinical Paradigm-1 examination into non-musier-invasive bladder cancerBusiness Wire•Feb 08, 2024•Prokarium
•
Prokarium Reaches Major Milestone with FDA Approval of an IND for Bladder Cancer ProgramBusiness Wire•Nov 02, 2023•Prokarium
•
Prokarium announces $30 million in funding aimed at bringing its lead program to the clinic and building a novel therapy platformBusiness Wire•Feb 09, 2023•Prokarium
•
•
Prokarium Strengthens Patent Position Through US Patent Grant Notification for Prime Immunotherapy in Combination with Cell TherapiesBusiness Wire•Oct 05, 2022•Prokarium
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Prokarium
Explore our recently published companies
- Marketing Agency - Deptford based, 2020 founded, Unfunded company
- Aquiyel Services - Houston based, 2020 founded, Public company
- B2clogin.com - 2017 founded, Unfunded company
- Compose Finance - Warsaw based, 2024 founded, Unfunded company
- Bubbls - United Kingdom based, Unfunded company
- TedhiMedhi Family - India based, Unfunded company
